RecruitingNCT07645898

Use of Continuous Glucose Monitoring to Evaluate Postprandial Response to Raw Cornstarch Supplementation in Adult Glycogen Storage Disease Type I

Continuous Glucose Monitoring in Adult Patients With Glycogen Storage Disease Type I and the Impact of Raw Cornstarch Addition to Meals on Postprandial Glycemic Response


Sponsor

Federico II University

Enrollment

8 participants

Start Date

Feb 5, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

The aim of this observational study is to evaluate the impact of raw cornstarch supplementation on postprandial glycemic response in adult patients with Glycogen Storage Disease type I (GSD I), using continuous glucose monitoring (CGM) systems.GSD I is a rare inherited metabolic disorder characterized by impaired glucose homeostasis during fasting, leading to recurrent hypoglycemia and metabolic abnormalities. Nutritional therapy, based on frequent carbohydrate intake and raw cornstarch supplementation, represents the cornerstone of treatment. However, the optimal timing of raw cornstarch administration in relation to meals and its effect on postprandial glycemic control remain unclear.The main question this study aims to answer is: "Does raw cornstarch intake during meals affect postprandial glycemic response in adult patients with Glycogen Storage Disease type I?". Additional objectives include evaluating whether dose and timing of cornstarch intake influences glucose profile, glycemic variability, hypoglycemic events, body composition, energy expenditure, and lipid profile. Participants will include adults with genetically confirmed GSD Ia or Ib who routinely use CGM systems and regularly consume raw cornstarch as part of their dietary management. This is a real-life observational study, and participants will continue their routine clinical care without receiving additional experimental treatments. After providing informed consent, participants will undergo clinical, metabolic, and nutritional assessments, including: * anthropometric measurements; * body composition analysis by bioelectrical impedance; * indirect calorimetry for resting energy expenditure; * handgrip strength evaluation; * biochemical analyses, including fasting glucose, HbA1c, lipid profile, liver enzymes, creatinine, uric acid, and lactate. CGM-derived parameters collected during the 14 days preceding the visit will be analyzed, including Time in Range (TIR), Time Above Range (TAR), Time Below Range (TBR), coefficient of variation (CV%), Glucose Management Indicator (GMI), and frequency of hypoglycemic episodes. Participants will also complete a 7-day food diary reporting meal timing, food intake, and raw cornstarch consumption. Investigators will compare meals consumed with and without raw cornstarch supplementation and evaluate postprandial glycemic trends. Postprandial glycemic response will be assessed using dynamic indices, including glucose peak, nadir, time to peak, time to nadir, glucose excursion rates, and incremental area under the curve (iAUC). Glucose values will be analyzed every 5 minutes for up to 4 hours after meals using CGM data. Inclusion criteria include: genetically confirmed GSD Ia or Ib, age \>18 years, routine CGM use, and habitual raw cornstarch consumption.Exclusion criteria include psychiatric disorders, pregnancy, celiac disease, dialysis treatment, nocturnal enteral feeding, and severe acute or chronic illnesses. Approximately 8 adult patients are expected to be enrolled. Risks for participants are considered minimal, as all procedures are part of routine clinical follow-up. Potential benefits include improved personalization of nutritional therapy and optimization of carbohydrate and raw cornstarch administration, potentially improving glycemic control and reducing metabolic complications in patients with GSD I.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • confirmed genetic diagnosis of GSD Ia or Ib;
  • age >18 years;
  • routine CGM use;
  • habitual raw cornstarch consumption.

Exclusion Criteria5

  • psychiatric disorders;
  • pregnancy, celiac disease;
  • dialysis treatment;
  • nocturnal enteral feeding;
  • severe acute or chronic illnesses.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

AOU Policlinico "Federico II"

Naples, Napoli, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07645898


Related Trials